Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

AM-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AM-Pharma Increases Funding To €163m For Phase-Iii Trial Of Recap In Sa-Aki

Details:

New capital to be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).

Lead Product(s): Ilofotase alfa

Therapeutic Area: Nephrology Product Name: recAP

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Cowen Healthcare Investments

Deal Size: $176.0 million Upfront Cash: Undisclosed

Deal Type: Funding March 31, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY